Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor + bevacizumab + TACE for hepatocellular carcinoma
ChiCTR2300068332Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in hepatocellular carcinoma (HCC), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoints: 6-month progression-free survival rate and adverse event. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300068332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068332.